Chongqing Sidemu Biotechnology Technology Company
Chongqing Sidemu Biotechnology Technology and sponsor Chongqing Public Health Medical Center disclosed March 27 they are recruiting patients for an up to 90-patient Phase I/II clinical trial (NCT04324996) assessing the company’s universal off-the-shelf NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and granulocyte-macrophage colony-stimulating factor (GM-CSF)-neutralizing single-chain variable fragment (scFv).
Technology:
COVID
Industry:
Treatments
Headquarters:
China
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership